CN113209156A - Ginseng composite traditional Chinese medicine composition - Google Patents
Ginseng composite traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN113209156A CN113209156A CN202110318264.1A CN202110318264A CN113209156A CN 113209156 A CN113209156 A CN 113209156A CN 202110318264 A CN202110318264 A CN 202110318264A CN 113209156 A CN113209156 A CN 113209156A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- composition
- ginseng
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 137
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 241000208340 Araliaceae Species 0.000 title claims abstract description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 36
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 36
- 239000002131 composite material Substances 0.000 title claims abstract description 17
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 37
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241001061264 Astragalus Species 0.000 claims abstract description 9
- 241000132012 Atractylodes Species 0.000 claims abstract description 9
- 210000004233 talus Anatomy 0.000 claims abstract description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 8
- 230000003511 endothelial effect Effects 0.000 claims abstract description 5
- 230000002792 vascular Effects 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 108090000695 Cytokines Proteins 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 210000004969 inflammatory cell Anatomy 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 238000000944 Soxhlet extraction Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 241000045403 Astragalus propinquus Species 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 27
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 4
- 241000092665 Atractylodes macrocephala Species 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- -1 stomach invigorating Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a ginseng composite traditional Chinese medicine composition which is characterized in that active ingredients of the ginseng composite traditional Chinese medicine composition are prepared from traditional Chinese medicine raw materials, wherein the traditional Chinese medicine raw materials comprise ginseng, astragalus, ligusticum wallichii, acanthopanax, white poria and bighead atractylodes rhizome. Can obviously inhibit the expression of inflammatory factors and the generation of vascular endothelial relaxation factors NO, and provides a new idea for Chinese medicine resistance.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine compositions, in particular to a ginseng composite traditional Chinese medicine composition.
Background
During the development of inflammation, macrophages present allergens as antigen presenting cells, which upon activation secrete large amounts of cytokines and chemokines to recruit more inflammatory cells to participate in the pathological process. The cytokines and chemokines are various protein molecules involved in inflammatory reactions, such as the CCL family of chemokines, the CXCL family, the IL family of interleukins, the CSF family of colony stimulating factors, the TNF family of tumor necrosis factors, and the like. Common inflammatory cytokines include interleukin 6(IL-6), interleukin 1B (IL-1B), and tumor necrosis factor (TNF-alpha), among others, which are cytokines that primarily influence the inflammatory process. TNF-alpha is the earliest and most important inflammatory mediator in the inflammatory response process, can induce the release of IL-6 cytokines, and can stimulate cells to release inflammatory mediators such as NO, oxygen free radicals and the like; IL1B is involved in a variety of inflammatory cell activities including cell proliferation, differentiation and apoptosis.
Inflammatory cytokines, typified by IL-6, IL1B, and TNF- α, have been shown to mediate and participate in the pathophysiological processes of a number of diseases. Not only is a large amount of inflammatory factors expressed in acute infection, but also chronic diseases such as diabetes, cardiovascular diseases and tumors are considered to be involved in chronic inflammation. Therefore, the development of drugs capable of inhibiting the expression of inflammatory cytokines and inflammatory mediators is essential for the treatment and clinical application of inflammatory diseases and allergic diseases.
Ginseng, a perennial herb of the family Araliaceae. Distributed in china, russia and korea; in China, the Chinese medicinal materials are distributed in the eastern part of Liaoning, the eastern half part of Jilin and the eastern part of Heilongjiang. Generally, the plants grow under deciduous and broad-leaved mixed forests with elevation of hundreds of meters. The succulent root of Ginseng radix is tonic, and is suitable for regulating blood pressure, recovering heart function, neurasthenia and asthenia, and also has expectorant, stomach invigorating, diuretic and exciting effects. However, the compound application of the compound preparation in the aspect of anti-inflammation is not reported at present.
Disclosure of Invention
The invention aims to solve the technical problem of how to provide a ginseng composite traditional Chinese medicine composition capable of inhibiting the expression of inflammatory cytokines and inflammatory mediators.
In order to solve the technical problems, the invention provides a ginseng composite traditional Chinese medicine composition, wherein active ingredients of the ginseng composite traditional Chinese medicine composition are prepared from traditional Chinese medicine raw materials, and the traditional Chinese medicine raw materials comprise ginseng, astragalus mongholicus, ligusticum wallichii, acanthopanax, poria cocos and bighead atractylodes rhizome.
The traditional Chinese medicine comprises the following raw materials in parts by weight: 10-30 parts of ginseng, 10-30 parts of astragalus, 20-60 parts of ligusticum wallichii, 20-50 parts of acanthopanax, 50-70 parts of bailing and 40-60 parts of bighead atractylodes rhizome.
Further, the traditional Chinese medicine raw materials comprise the following components: 11 parts of ginseng, 23 parts of astragalus, 43 parts of ligusticum wallichii, 35 parts of acanthopanax, 52 parts of bailing and 55 parts of bighead atractylodes rhizome.
The ginseng composite traditional Chinese medicine composition is applied to reducing the expression of inflammatory cytokine genes or inhibiting the release amount of inflammatory mediators of inflammatory cells.
The preparation method of the ginseng composite traditional Chinese medicine composition is characterized by comprising the following steps:
1) weighing Ginseng radix, radix astragali, rhizoma Ligustici Chuanxiong, radix Acanthopanacis Senticosi, Poria and Atractylodis rhizoma according to proportion, respectively, and pulverizing the weighed Ginseng radix, radix astragali, rhizoma Ligustici Chuanxiong, radix Acanthopanacis Senticosi, Poria and Atractylodis rhizoma to obtain powdered mixture;
2) extracting the powdered mixture with ethanol water solution, collecting extractive solution, concentrating, and drying to obtain crude product of Chinese medicinal composition;
3) further extracting the crude product with pure water, collecting extractive solution, concentrating, and drying to obtain the final product.
The granularity of the powdery mixture in the step 1) is 100 meshes.
The extraction method in the step 2) is a Soxhlet extraction method, the extraction time is 5 hours, and the volume ratio of the ethanol water solution to the powdery mixture is 15: 1.
The drying temperature in the step 2) is 120 ℃.
The extraction method in the step 3) is a Soxhlet extraction method, the extraction time is 3 hours, and the volume ratio of pure water to the crude product of the traditional Chinese medicine composition is 50: 1.
The concentration and drying steps in the step 3) are as follows: the extract was concentrated to 2ml and lyophilized for 16 hours.
The preparation method of the ginseng composite traditional Chinese medicine composition is applied to reducing the expression of inflammatory cytokine genes or inhibiting the release amount of inflammatory mediators of inflammatory cells.
In the traditional Chinese medicine composition, the inflammatory cytokine gene can be TNF-alpha gene and/or IL-6 gene.
The inflammatory mediator may be vascular endothelial relaxation factor NO.
The traditional Chinese medicine composition or the preparation method of the traditional Chinese medicine composition is applied to preparation of medicines for inhibiting expression of inflammatory cytokines.
The medicine prepared by taking the pharmaceutical composition as the active ingredient also belongs to the protection scope of the invention. The pharmaceutical composition can be directly prepared or prepared after adding pharmaceutically acceptable auxiliary materials, and can be prepared into any pharmaceutically acceptable dosage form. Examples of oral dosage forms include: capsule, tablet, granule, powder, pill, dripping pill, sustained-release preparation, oral liquid, mixture, and syrup; the external preparation includes, for example: ointment, suppository, patch, medicated wine, tincture, gel, liniment, aerosol, spray and plastics. The medicaments in various dosage forms can be prepared according to the conventional method in the pharmaceutical field.
The ginseng composite traditional Chinese medicine composition can inhibit the expression of inflammatory factors in a plurality of inflammatory cells; can also inhibit the release of inflammatory mediators. Can remarkably reduce the expression of inflammatory factors such as IL-6 and/or TNF-alpha and inhibit the generation of vascular endothelial relaxation factor NO.
Detailed Description
The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the invention. The examples provided below serve as a guide for further modifications by a person skilled in the art and do not constitute a limitation of the invention in any way.
The experimental procedures in the following examples are conventional unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1
1. Preparation of Chinese medicinal composition 1
According to the mass of each component in the traditional Chinese medicine composition 1 given in table 1, ginseng, astragalus, ligusticum wallichii, acanthopanax, bailing and bighead atractylodes rhizome are weighed, respectively crushed to 100 meshes and mixed to obtain a powdery mixture.
Extracting the powdery mixture with 90% ethanol water solution at a volume ratio of 15:1, Soxhlet extracting at 85 deg.C for 5 hr, collecting extractive solution, further concentrating, drying at 120 deg.C to obtain crude product 1 of Chinese medicinal composition;
further extracting the crude Chinese medicinal composition 1 with pure water at a volume ratio of 50:1 at 100 deg.C for 3 hr, collecting extractive solution, further concentrating to 2ml, and lyophilizing under reduced pressure for 16 hr to obtain the final product 1.
2. Preparation of Chinese medicinal composition 2
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in the step 1 was replaced with the "mass of each component in the Chinese medicinal composition 2 given in table 1" and the other steps were kept unchanged to obtain the Chinese medicinal composition 2.
3. Preparation of Chinese medicinal composition 3
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in step 1 was replaced with the "mass of each component in the Chinese medicinal composition 3 given in table 1" and the other steps were kept unchanged to obtain the Chinese medicinal composition 3.
4. Preparation of Chinese medicinal composition 4
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in the step 1 was replaced with the "mass of each component in the Chinese medicinal composition 4 given in table 1" and the other steps were kept unchanged to obtain the Chinese medicinal composition 4.
5. Preparation of Chinese medicinal composition 5
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in the step 1 was replaced with the "mass of each component in the Chinese medicinal composition 5 given in table 1" and the other steps were kept unchanged to obtain the Chinese medicinal composition 5.
6. Preparation of Chinese medicinal composition 6
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in step 1 was replaced with the "mass of each component in the Chinese medicinal composition 6 given in table 1" and the other steps were kept unchanged to obtain the Chinese medicinal composition 6.
7. Preparation of Chinese medicinal composition 7
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in step 1 was replaced with the "mass of each component in the Chinese medicinal composition 7 given in table 1" and the other steps were kept unchanged to obtain the Chinese medicinal composition 7.
TABLE 1 weight of each component of the Chinese medicinal composition 1-7
8. Preparation of comparative composition 1
The mass of each component in the traditional Chinese medicine composition 1 given in table 1 in 1 was replaced with "11 g of ginseng, 23g of astragalus, 43g of ligusticum wallichii, and 35g of acanthopanax senticosus" and the other steps were kept unchanged to obtain a comparative composition 1.
9. Preparation of comparative composition 1
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in 1 was replaced with "11 g of ginseng, 23g of astragalus, 52g of white poria and 55g of white atractylodes rhizome" and the other steps were kept unchanged to obtain a comparative composition 2.
10. Preparation of comparative composition 1
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in 1 was replaced with "11 g of ginseng, 23g of astragalus, 43g of ligusticum wallichii, 55g of atractylodes macrocephala" and the other steps were kept unchanged, to obtain comparative composition 3.
11. Preparation of comparative composition 1
The "mass of each component in the Chinese medicinal composition 1 given in table 1" in 1 was replaced with "11 g of ginseng, 43g of ligusticum wallichii, 35g of acanthopanax, 52g of poria cocos, 55g of atractylodes macrocephala" and the other steps were kept unchanged, to obtain a comparative composition 4.
12. Preparation of comparative composition 1
The mass of each component in the Chinese medicinal composition 1 given in table 1 in 1 was replaced with 23g of astragalus root, 43g of ligusticum wallichii, 35g of acanthopanax root, 52g of white poria and 55g of atractylodes macrocephala, and the other steps were kept unchanged, to obtain a comparative composition 5.
Example 2
Influence of Ginseng radix compound Chinese medicinal composition on expression of inflammatory cytokine IL-6 and TNF-alpha
1. Influence of traditional Chinese medicine composition 1 on expression of inflammatory cytokines IL-6 and TNF-alpha
1g of the Chinese medicinal composition 1 prepared in example 1 was weighed and dissolved in 10ml of dimethyl sulfoxide to obtain a Chinese medicinal composition solution 1. The method for detecting the influence of the traditional Chinese medicine composition solution 1 on the expression of inflammatory cytokines IL-6 and TNF-alpha by utilizing a qPCR technology specifically comprises the following steps:
1) THP1 cells (acute myelogenous leukemia cells, national experimental cell resource sharing service platform) are paved in a 12-well plate at 40 ten thousand per well, and 100ng/mL PMA (Sigma) is added to treat the cells for 24h, so that the cells are induced into macrophages, and at the moment, the cells are converted from a suspension state to an adherent state.
2) Adding 0.1ml of the Chinese medicinal composition solution 1 and 100. mu.g of LPS to 100ml of the cell suspension obtained in step 1, and culturing at 37 ℃ for 24 hours.
3) The RNA of the cells in the kit steps is used and inverted to cDNA.
4) Using the cDNA obtained in step 3) as a template, and using an IL-6 primer (IL-6-F: GGCCCTTGCTTTCTCTTCG (SEQ ID NO: 1); ATAATAAAGTTTTGATTATGT (SEQ ID NO: 2)) pairs were subjected to a qPCR reaction, procedure: at 95 ℃ for 3 min; (95 ℃, 3 s; 60 ℃, 30s)40 cycles.
5) Using the cDNA obtained in the step 3) as a template, and respectively using TNF-alpha primers (TNF-alpha-F: CCTCTCTCTAATCAGCCCTCTG (sequence 3); GAGGACCTGGGAGTAGATGAG (seq. No. 4)) pairs were subjected to qPCR reactions, program: at 95 ℃ for 3 min; (95 ℃, 3 s; 60 ℃, 30s)40 cycles.
The experiment was repeated 5 times and the results recorded.
2. Influence of Chinese medicinal composition-7 on expression of inflammatory cytokines IL-6 and TNF-alpha
Replacing the traditional Chinese medicine composition 1 in the step 1 with a traditional Chinese medicine composition 2, a traditional Chinese medicine composition 3, a traditional Chinese medicine composition 4, a traditional Chinese medicine composition 5, a traditional Chinese medicine composition 6, a traditional Chinese medicine composition 7, a comparative composition 1, a comparative composition 2, a comparative composition 3, a comparative composition 4 and a comparative composition 5 respectively, keeping the other steps unchanged, repeating the experiment of each group for 5 times, and recording the experiment result.
3. Experimental setup for blank control group and Induction control group
Induction control group: adding 0.1ml of the Chinese medicinal composition solution 1 and 100. mu.g of LPS to 100ml of the cell suspension obtained in step 1 in step 2) of step 1, and culturing at 37 ℃ for 24 hours. "replacement" 100ml of the cell suspension obtained in step 1 was added with 0.1ml of dimethyl sulfoxide and 100. mu.g of LPS, and cultured at 37 ℃ for 24 hours. The other steps are not changed and are repeated for 5 times to obtain the experimental result of the induction control group.
Blank control group: adding 0.1ml of the Chinese medicinal composition solution 1 and 100. mu.g of LPS to 100ml of the cell suspension obtained in step 1 in step 2) of step 1, and culturing at 37 ℃ for 24 hours. "replace" 100ml of the cell suspension obtained in step 1 was added with 0.1ml of dimethyl sulfoxide and cultured at 37 ℃ for 24 hours. The other steps are not changed and are repeated for 5 times to obtain the experimental result of the blank control group.
The gene expression level of the blank control group is 1, the gene expression level of the drug treatment group is higher than 1, the gene expression is up-regulated and lower than 1, the results are shown in table 2, and the numerical values in table 2 are the average values of 5 experiments.
Table 2 qPCR results for experimental groups in example 2
As can be seen from the data in Table 1, under normal conditions, the level of the inflammatory factor expressed by the macrophages is at a very low level, i.e., the blank control group, and the level of the inflammatory factor expressed by the macrophages is rapidly increased during the inflammatory process. On the basis of LPS induction, the traditional Chinese medicine compositions 1-7 and the comparative compositions 1-5 prepared in the embodiment 1 of the invention are added, so that the inflammation level of cell expression is reduced, and the traditional Chinese medicine compositions 1-7 and the comparative compositions 1-5 in the embodiment 1 can down-regulate the expression of inflammatory cytokine genes IL-6 and TNF-alpha, wherein the inhibition effect of the traditional Chinese medicine compositions 1-7 on the expression of the inflammatory cytokine genes IL-6 and TNF-alpha is better than that of the comparative compositions 1-5. In the traditional Chinese medicine compositions 1-7, the traditional Chinese medicine composition 5 has better inhibition effect on the expression of inflammatory cytokine genes IL-6 and TNF-alpha than other six types, and can achieve the inhibition rate of more than 70 percent, and the traditional Chinese medicine composition 5 has the best anti-inflammatory effect.
Example 3
Influence of traditional Chinese medicine composition on release amount of vascular endothelial relaxation factor NO of inflammatory cells
The supernatants of the traditional Chinese medicine composition 1-7, the comparative composition 1-5, the blank control group and the induction control group in the example 2) after being cultured for 24 hours at 37 ℃ are respectively collected, and the NO content is calculated by reading the supernatants at 550nm by using a kit of the nitroreductase method and an enzyme reader.
The blank control group had NO content of 1, the drug treatment group had NO content greater than 1, and the drug treatment group had NO content less than 1, and the results are shown in table 3, where the values in table 3 are all the average values of 5 experiments.
TABLE 3 comparison of NO release amounts by different treatment methods
| NO content | |
| Blank control group | 1 |
| Induction control group | 12.33 |
| Chinese medicinal composition 1 | 4.56 |
| Chinese medicinal composition 2 | 4.68 |
| Chinese medicinal composition 3 | 4.58 |
| Chinese medicinal composition 4 | 4.28 |
| Chinese medicinal composition 5 | 1.98 |
| Chinese medicinal composition 6 | 4.35 |
| Chinese medicinal composition 7 | 4.68 |
| Comparative composition 2 | 6.02 |
| Comparative composition 2 | 6.11 |
| Comparative composition 3 | 5.85 |
| Comparative composition 4 | 5.94 |
| Comparative composition 5 | 6.08 |
As can be seen from table 3, under normal conditions, macrophages release little NO, i.e. the blank control group shown in table 3. During the inflammation process, the NO released from macrophages is rapidly increased, in this example, LPS is used to induce macrophages to generate a large amount of NO, which is intended to simulate the pathological process of inflammation occurrence in human body, i.e., the induction control group shown in Table 3. When the traditional Chinese medicine compositions 1 to 7 and the comparative compositions 1 to 5 prepared in the embodiment 1 of the invention are added while LPS induction is carried out, NO released by cells is reduced, and the traditional Chinese medicine compositions 1 to 7 and the comparative compositions 1 to 5 prepared in the embodiment 1 of the invention have certain anti-inflammatory effect. Wherein the down-regulation effect of the traditional Chinese medicine composition 1-7 on the content of NO released by inflammatory cells is better than that of the comparative composition 1-5. In the traditional Chinese medicine compositions 1-7, the traditional Chinese medicine composition 5 has better down-regulation effect on the content of NO released by inflammatory cells than other six types, so that the content of NO released by inflammatory cells is down-regulated to 1/6 smaller than an induction control, and the traditional Chinese medicine composition 5 has the best anti-inflammatory effect.
The present invention has been described in detail above. It will be apparent to those skilled in the art that the invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with reference to specific embodiments, it will be appreciated that the invention can be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The use of some of the essential features is possible within the scope of the claims attached below.
Claims (10)
1. The ginseng composite traditional Chinese medicine composition is characterized in that active ingredients of the ginseng composite traditional Chinese medicine composition are prepared from traditional Chinese medicine raw materials, wherein the traditional Chinese medicine raw materials comprise ginseng, astragalus membranaceus, ligusticum wallichii, acanthopanax, white poria and bighead atractylodes rhizome.
2. The composition of claim 1, wherein the composition of the traditional Chinese medicine raw materials comprises the following components in percentage by weight: 10-30 parts of ginseng, 10-30 parts of astragalus, 20-60 parts of ligusticum wallichii, 20-50 parts of acanthopanax, 50-70 parts of bailing and 40-60 parts of bighead atractylodes rhizome.
3. The composition of claim 1, wherein the composition of the traditional Chinese medicine raw materials is as follows: 11 parts of ginseng, 23 parts of astragalus, 43 parts of ligusticum wallichii, 35 parts of acanthopanax, 52 parts of bailing and 55 parts of bighead atractylodes rhizome.
4. Use of the ginseng composite traditional Chinese medicine composition according to any one of claims 1 to 3 in reducing the expression of inflammatory cytokine genes or inhibiting the release amount of inflammatory mediators of inflammatory cells or preparing drugs for inhibiting the expression of inflammatory cytokines.
5. The preparation method of the ginseng composite traditional Chinese medicine composition is characterized by comprising the following steps:
1) weighing Ginseng radix, radix astragali, rhizoma Ligustici Chuanxiong, radix Acanthopanacis Senticosi, Poria and Atractylodis rhizoma according to proportion, respectively, and pulverizing the weighed Ginseng radix, radix astragali, rhizoma Ligustici Chuanxiong, radix Acanthopanacis Senticosi, Poria and Atractylodis rhizoma to obtain powdered mixture;
2) extracting the powdered mixture with ethanol water solution, collecting extractive solution, concentrating, and drying to obtain crude product of Chinese medicinal composition;
3) further extracting the crude product with pure water, collecting extractive solution, concentrating, and drying to obtain the final product.
6. The method as claimed in claim 5, wherein the particle size of the powdery mixture in the step 1) is 100 mesh.
7. The method according to claim 5, wherein the extraction method in step 2) is a Soxhlet extraction method, the extraction time is 5 hours, and the volume ratio of the ethanol water solution to the powdery mixture is 15: 1; the drying temperature was 120 ℃.
8. The method as claimed in claim 5, wherein the extraction method in step 3) is Soxhlet extraction, the extraction time is 3 hours, and the volume ratio of pure water to crude Chinese medicinal composition is 50: 1; the concentration and drying steps in the step 3) are as follows: the extract was concentrated to 2ml and lyophilized for 16 hours.
9. The use of the method for preparing the ginseng composite traditional Chinese medicine composition according to any one of claims 5 to 8 for reducing the expression of inflammatory cytokine genes or inhibiting the release of inflammatory mediators of inflammatory cells or preparing a medicament for inhibiting the expression of inflammatory cytokines.
10. The use according to claim 4 or 9, wherein the inflammatory cytokine gene is TNF-a gene and/or IL-6 gene; the inflammatory mediator may be vascular endothelial relaxation factor NO.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110318264.1A CN113209156B (en) | 2021-03-25 | 2021-03-25 | Ginseng composite traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110318264.1A CN113209156B (en) | 2021-03-25 | 2021-03-25 | Ginseng composite traditional Chinese medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113209156A true CN113209156A (en) | 2021-08-06 |
| CN113209156B CN113209156B (en) | 2024-09-06 |
Family
ID=77084109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110318264.1A Active CN113209156B (en) | 2021-03-25 | 2021-03-25 | Ginseng composite traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113209156B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1733180A (en) * | 2005-08-01 | 2006-02-15 | 颜怀玮 | Medicine, food used article for preventing and curing acute gastroenteritis and method for producing the same |
| CN101417004A (en) * | 2007-10-22 | 2009-04-29 | 洛阳普莱柯生物工程有限公司 | Preparation method of animal medicine capable of refrigerating, relieving inflammation, nourishing the liver and promoting the gallbladder |
| KR20160081870A (en) * | 2016-03-31 | 2016-07-08 | 대전대학교 산학협력단 | the gamichunggisan composite with the fuction of antioxidation and antiphlogistics |
| CN105983051A (en) * | 2015-02-16 | 2016-10-05 | 无限极（中国）有限公司 | External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof |
| CN105997861A (en) * | 2016-07-11 | 2016-10-12 | 山西普德药业有限公司 | Ginseng polysaccharide injection and preparing method thereof |
| CN106177001A (en) * | 2016-09-08 | 2016-12-07 | 湖南灼华生物科技有限公司 | For Chinese medicine composition improving cardiac edema and its preparation method and application |
| CN111643628A (en) * | 2020-06-24 | 2020-09-11 | 博奥生物集团有限公司 | Traditional Chinese medicine for regulating inflammation and/or fibrosis related signal pathway and application thereof |
-
2021
- 2021-03-25 CN CN202110318264.1A patent/CN113209156B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1733180A (en) * | 2005-08-01 | 2006-02-15 | 颜怀玮 | Medicine, food used article for preventing and curing acute gastroenteritis and method for producing the same |
| CN101417004A (en) * | 2007-10-22 | 2009-04-29 | 洛阳普莱柯生物工程有限公司 | Preparation method of animal medicine capable of refrigerating, relieving inflammation, nourishing the liver and promoting the gallbladder |
| CN105983051A (en) * | 2015-02-16 | 2016-10-05 | 无限极（中国）有限公司 | External traditional Chinese medicine composition and preparation with functions of relieving allergy and resisting inflammation and preparation method thereof |
| KR20160081870A (en) * | 2016-03-31 | 2016-07-08 | 대전대학교 산학협력단 | the gamichunggisan composite with the fuction of antioxidation and antiphlogistics |
| CN105997861A (en) * | 2016-07-11 | 2016-10-12 | 山西普德药业有限公司 | Ginseng polysaccharide injection and preparing method thereof |
| CN106177001A (en) * | 2016-09-08 | 2016-12-07 | 湖南灼华生物科技有限公司 | For Chinese medicine composition improving cardiac edema and its preparation method and application |
| CN111643628A (en) * | 2020-06-24 | 2020-09-11 | 博奥生物集团有限公司 | Traditional Chinese medicine for regulating inflammation and/or fibrosis related signal pathway and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 姜华;等: "3种中药复方血清对脂多糖诱导的人脐静脉内皮细胞炎症因子LOX-1、TNF-α、VCAM-1和ICAM-1表达的影响", 中国动脉硬化杂志, vol. 23, no. 10, pages 985 - 988 * |
| 改针;等: "心脑宁片对不稳定型心绞痛患者血清WBC、hs-CRP含量的影响", 中西医结合心脑血管病杂志, vol. 13, no. 03, pages 336 - 337 * |
| 陆志明, 等: "黄芪、川芎小复方制剂对伴微量白蛋白尿的2型糖尿病患者血管内皮细胞保护作用及其机制研究", 四川大学学报(医学版), vol. 36, no. 04, pages 529 - 532 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113209156B (en) | 2024-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105131142B (en) | Industrialization production method and application of acanthopanax senticosus polysaccharide | |
| CN113209166A (en) | Anti-aging traditional Chinese medicine composition containing nicotinamide mononucleotide and preparation method thereof | |
| CN113209156A (en) | Ginseng composite traditional Chinese medicine composition | |
| CN108904521B (en) | Antitumor drug containing polysaccharide of radix pseudostellariae and using method thereof | |
| CN103520376A (en) | Chinese medicine health-maintenance preparation with auxiliary hypoglycemic activity | |
| CN1105594A (en) | Jiangailing pill | |
| EP2857029B1 (en) | Composition for use in preventing and treating leukopenia caused by radiotherapy and chemotherapy | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN106620440B (en) | Prescription for cough | |
| CN114425058B (en) | Traditional Chinese medicine composition for treating rhinitis and preparation method, medicine and preparation thereof | |
| CN114306520B (en) | Traditional Chinese medicine ointment formula for treating parkinsonism dysphagia and preparation method thereof | |
| US11622989B2 (en) | Method for inhibiting melanoma cell metastasis | |
| CN103494894A (en) | Traditional Chinese medicine composition with effect of reducing blood sugar, as well as preparation method and application thereof | |
| CN113181259B (en) | Children's astragalus-ginseng cold-treating granule and its prepn | |
| CN109394968B (en) | Composition with auxiliary blood sugar reducing function and application thereof | |
| CN108553490B (en) | Application of imitation chestnut leaves and antitumor drug | |
| CN118021890A (en) | Traditional Chinese medicine with analgesic effect and application thereof in preparation of medicines with analgesic effect | |
| CN107693618B (en) | Pharmaceutical composition for treating kidney deficiency and preparation method and application thereof | |
| CN117462629A (en) | Traditional Chinese medicine composition for preventing and treating adverse reactions related to tumor immunotherapy as well as preparation method and application thereof | |
| CN101618065A (en) | Lucid ganoderma complex health care product | |
| CN118593599A (en) | Traditional Chinese medicine composition, preparation method thereof and application of traditional Chinese medicine composition in preparation of medicines with effect of treating thalassemia | |
| CN117044912A (en) | Propolis composition for improving immunity and preparation method and application thereof | |
| CN116270908A (en) | Application of vetiver product in preparation of medicines for improving animal immunity and resisting inflammation | |
| CN117462624A (en) | Novel anticancer Chinese medicinal compound preparation and preparation method thereof | |
| CN115120609A (en) | Traditional Chinese medicine polysaccharide composition for inhibiting estrogen expression and protecting mammary gland and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |